|
|
|
@ -110,7 +110,9 @@ it continues to completion.
|
|
|
|
\tikzfig{../assets/tikzit/CausalGraph2}
|
|
|
|
\tikzfig{../assets/tikzit/CausalGraph2}
|
|
|
|
}
|
|
|
|
}
|
|
|
|
}
|
|
|
|
}
|
|
|
|
|
|
|
|
\todo{check if this is the correct graph}
|
|
|
|
\caption{Graphical Causal Model}
|
|
|
|
\caption{Graphical Causal Model}
|
|
|
|
|
|
|
|
|
|
|
|
% \small{Crimson boxes are the variables of interest,
|
|
|
|
% \small{Crimson boxes are the variables of interest,
|
|
|
|
% white boxes are unobserved, while the gray boxes will be controlled for.}
|
|
|
|
% white boxes are unobserved, while the gray boxes will be controlled for.}
|
|
|
|
\label{Fig:CausalModel}
|
|
|
|
\label{Fig:CausalModel}
|
|
|
|
@ -119,9 +121,10 @@ it continues to completion.
|
|
|
|
|
|
|
|
|
|
|
|
% Constructing the model more explicitly
|
|
|
|
% Constructing the model more explicitly
|
|
|
|
% - quickly describe each node and line.
|
|
|
|
% - quickly describe each node and line.
|
|
|
|
% TODO: double check which graphic to use.
|
|
|
|
\todo{I think I need to blend the data section in before this, to give some overall information on data.}
|
|
|
|
|
|
|
|
\todo{I may need to add some information on snapshots so that this makes sense.}
|
|
|
|
|
|
|
|
|
|
|
|
A quick summary of the nodes of the DAG and their impact:
|
|
|
|
A quick summary of the nodes of the DAG, the exact representation in the data, and their impact:
|
|
|
|
\begin{itemize}
|
|
|
|
\begin{itemize}
|
|
|
|
\item Main Interests (Crimson Boxes)
|
|
|
|
\item Main Interests (Crimson Boxes)
|
|
|
|
\begin{enumerate}
|
|
|
|
\begin{enumerate}
|
|
|
|
@ -129,21 +132,34 @@ A quick summary of the nodes of the DAG and their impact:
|
|
|
|
If the final status of the trial was \textit{terminated}
|
|
|
|
If the final status of the trial was \textit{terminated}
|
|
|
|
or \textit{completed}.
|
|
|
|
or \textit{completed}.
|
|
|
|
\item \texttt{Enrollment Status}:
|
|
|
|
\item \texttt{Enrollment Status}:
|
|
|
|
Measure of whether enrollment is progressing.
|
|
|
|
This describes the current enrollment status of the snapshot, e.g.
|
|
|
|
|
|
|
|
\texttt{Recruiting},
|
|
|
|
|
|
|
|
\texttt{Enrolling by invitation only},
|
|
|
|
|
|
|
|
or
|
|
|
|
|
|
|
|
\texttt{Active, not recruting}.
|
|
|
|
\item \texttt{Market Measures}:
|
|
|
|
\item \texttt{Market Measures}:
|
|
|
|
Various measures of the number of alternate drugs on the market.
|
|
|
|
Various measures of the number of alternate drugs on the market.
|
|
|
|
|
|
|
|
These are either the number of other drugs with the same active ingredient as the trial
|
|
|
|
|
|
|
|
(both generic and originators),
|
|
|
|
|
|
|
|
and those considered alternatives in various formularies published by the United States Pharmacopeia.
|
|
|
|
\end{enumerate}
|
|
|
|
\end{enumerate}
|
|
|
|
\item Observed Confounders (Gray Boxes)
|
|
|
|
\item Observed Confounders (Gray Boxes)
|
|
|
|
\begin{enumerate}
|
|
|
|
\begin{enumerate}
|
|
|
|
\item \texttt{Condition}:
|
|
|
|
\item \texttt{Condition}:
|
|
|
|
The underlying condition.
|
|
|
|
The underlying condition, classified by IDC-10 group.
|
|
|
|
This impacts every other aspect of the model.
|
|
|
|
This impacts every other aspect of the model.
|
|
|
|
\item \texttt{Population (market size)}:
|
|
|
|
\item \texttt{Population (market size)}:
|
|
|
|
Multiple measures of the impact the disease has (in DALYs).
|
|
|
|
Multiple measures of the impact the disease.
|
|
|
|
|
|
|
|
These are measured by the DALY cost of the disease in countries that have a
|
|
|
|
|
|
|
|
High, High-Medium, Medium, Medium-Low, and Low development scores.
|
|
|
|
|
|
|
|
This data comes from the Institute for Health Metrics' Global Burden of Disease study.
|
|
|
|
\item \texttt{Elapsed Duration}:
|
|
|
|
\item \texttt{Elapsed Duration}:
|
|
|
|
A normalized measure of the trial progression.
|
|
|
|
A normalized measure of the time elapsed in the trial.
|
|
|
|
|
|
|
|
Comes from the original estimate of the trial's primary completion date and the registered start date.
|
|
|
|
|
|
|
|
I take the difference in days between these, and get the percentage of that time that has elapsed.
|
|
|
|
\item \texttt{Decision to Proceed with Phase III}:
|
|
|
|
\item \texttt{Decision to Proceed with Phase III}:
|
|
|
|
If the compound development has progressed to Phase III.
|
|
|
|
If the compound development has progressed to Phase III.
|
|
|
|
|
|
|
|
This is included in the analysis by only including Phase III trials.
|
|
|
|
\end{enumerate}
|
|
|
|
\end{enumerate}
|
|
|
|
\item Unobserved Confounders (White Boxes)
|
|
|
|
\item Unobserved Confounders (White Boxes)
|
|
|
|
\begin{enumerate}
|
|
|
|
\begin{enumerate}
|
|
|
|
@ -152,8 +168,11 @@ A quick summary of the nodes of the DAG and their impact:
|
|
|
|
Cannot be observed, only estimated through scientific study.
|
|
|
|
Cannot be observed, only estimated through scientific study.
|
|
|
|
\item \texttt{Previously observed Efficacy and Safety}:
|
|
|
|
\item \texttt{Previously observed Efficacy and Safety}:
|
|
|
|
The information gathered in previous studies.
|
|
|
|
The information gathered in previous studies.
|
|
|
|
|
|
|
|
This is not available in my dataset because I don't have links to prior studies.
|
|
|
|
\item \texttt{Currently observed Efficiency and Safety}:
|
|
|
|
\item \texttt{Currently observed Efficiency and Safety}:
|
|
|
|
The information gathered during this study.
|
|
|
|
The information gathered during this study.
|
|
|
|
|
|
|
|
This is only partially available, and so is treated as unavailable.
|
|
|
|
|
|
|
|
After a study is over, the investigators are supposed to publish information about adverse events.
|
|
|
|
\end{enumerate}
|
|
|
|
\end{enumerate}
|
|
|
|
\end{itemize}
|
|
|
|
\end{itemize}
|
|
|
|
|
|
|
|
|
|
|
|
|